Literature DB >> 21947651

The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.

Yi Ma1, Xiaomeng Hao, Sheng Zhang, Jin Zhang.   

Abstract

The purpose of the study was to detect the effect and possible mechanism of human umbilical cord mesenchymal stem cells (hUCMSCs) on the in vitro and in vivo growth of stem cells isolated from primary human breast cancer cells and cell lines MDA-MB-231 and MCF-7. Primary human breast cancer cells and MDA-MB-231 and MCF-7 cells were sorted in vitro using flow cytometry, and the ESA+, CD44+, CD24-/low cells were isolated as breast cancer stem cells (CSCs). The inhibitory effect of hUCMSCs on CSCs was examined using the Cell Counting Kit-8 cell proliferation and soft agar colony formation assay. In vivo tumor inhibition was studied using a severe combined immunodeficient xenograft mouse model transplanted with MDA-MB-231 breast CSCs. The expression of phosphoinositide 3-kinase (PI3K) and AKT was examined in the xenograft tumors using immunohistochemistry. The number of colonies formed by breast CSCs co-cultured with hUCMSCs at the bottom of soft agar was significantly lower than those formed by the control group (P < 0.01). Compared with the control group, the CSCs co-cultured with hUCMSCs showed a higher number of cells in the G2-M phase (P < 0.05) and an increased number of apoptotic cells (P < 0.01). The mice in the medium- and high-concentration hUCMSC treatment groups exhibited clearly reduced tumor volume and tumor weight, compared with the control group (P < 0.01). Compared with the saline group, the xenograft tumor tissues from the mice treated with different concentrations of hUCMSCs showed significantly reduced levels of PI3K and AKT proteins (P < 0.001). In conclusion, hUCMSC significantly inhibited the growth of breast CSCs in vitro and in vivo. The underlying mechanism is likely related to cell cycle arrest, induction of tumor cell apoptosis, and suppressed activities of PI3K and AKT protein kinases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947651     DOI: 10.1007/s10549-011-1774-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

1.  Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy.

Authors:  Liang Leng; Yuebing Wang; Ningning He; Di Wang; Qianjie Zhao; Guowei Feng; Weijun Su; Yang Xu; Zhongchao Han; Deling Kong; Zhen Cheng; Rong Xiang; Zongjin Li
Journal:  Biomaterials       Date:  2014-03-29       Impact factor: 12.479

2.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

Review 3.  The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord.

Authors:  Ariff Bongso; Chui-Yee Fong
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

4.  Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.

Authors:  Yan Liu; Xiaobei Zhang; Jingjing Liu; Guofang Hou; Sheng Zhang; Jin Zhang
Journal:  Tumour Biol       Date:  2013-09-08

5.  Human Wharton's jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells.

Authors:  Hao Daniel Lin; Chui Yee Fong; Arijit Biswas; Mahesh Choolani; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2014-08       Impact factor: 5.739

6.  Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.

Authors:  Daniel Hao Lin; Arijit Biswas; Mahesh Choolani; Chui-Yee Fong; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

7.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

Review 8.  Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.

Authors:  Hoda Elkhenany; Ahmed Shekshek; Mohamed Abdel-Daim; Nagwa El-Badri
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

10.  Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (DKK1).

Authors:  Shanshan Ma; Shuo Liang; Hongliang Jiao; Liankai Chi; Xinyi Shi; Yi Tian; Bo Yang; Fangxia Guan
Journal:  Mol Cell Biochem       Date:  2013-10-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.